CD8A and breast cancer: Unlike the E75-pulsed DC vaccine, another HER2-derived peptide (AE37) pulsed-DC vaccine aimed to primarily elicit the CD4+ T cell response, not the CD8+ T cell response, and was shown to be safe and capable of generating durable immune responses and ultimately preventing BC recurrence in a clinical trial (30).